Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LuPARP: 177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours
NCT04375267Phase 1Completed
- Sponsor
- Region Västra Götaland
- Start
- Apr 2020
- Primary completion
- Jun 2024
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lutetium Lu 177 dotatate and olaparib in Neuroendocrine Neoplasm (NEN), thymoma, mesothelioma and 1 more, sponsored by Region Västra Götaland. Primary endpoint: Number of participants with treatment-related adverse events. Started Apr 2020; status: completed.
02
Drugs
lutetium Lu 177 dotatateolaparib
03
Conditions
Neuroendocrine Neoplasm (NEN)thymomamesotheliomameningioma
Beyond the preview
Go deeper on NCT04375267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04375267.